The possibility to analyse the tumour genetic material shed in the blood is undoubtedly one
of the main achievements of translational research in the latest years. In the modern clinical …

Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …

Lung adenocarcinoma (LUAD) belongs to a subgroup of non-small cell lung cancer
(NSCLC) with an increasing incidence all over the world. Tanshinone IIA (TSA), an active …

Cancer is serious endangers human life. After a long period of research and accumulation,
people's understanding of cancer and the corresponding treatment methods are constantly …

With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC),
expanding the targeted therapeutic options improved the survival and safety. However …

Background Developing liquid biopsy technology with higher sensitivity and specificity
especially for low-frequency mutations remains crucial. This study demonstrated superior …

Importance The inability to obtain a pathological diagnosis in a certain proportion of patients
with clinically diagnosed advanced lung cancer impedes precision treatment in clinical …

Background In most studies, patients with EGFR L858R mutant non-small cell lung cancer
(NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy …

Lung adenocarcinoma (LUAD) is a malignant respiratory disease, resulting in a heavy social
burden. Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance …

This systematic review with embedded meta-analysis aimed to evaluate the clinical utility of
circulating tumor DNA (ctDNA) in lung cancer. After screening and review of the Embase …